肿瘤细胞减灭术联合腹腔热灌注化疗治疗卵巢癌的Meta分析  

Meta-analysis of Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for ovarian cancer

作　　者：荆美玲 黄成日 俞星[3] JING Meiling;HUANG Chengri;YU Xing(Medical College of Yanbian University,Yanji 133002,China;Department of Obstetrics and Gynecology,Yantai Affiliated Hospital,Shandong Medical University,Yantai 264000,China;Department of Preventive Medicine,Medical College of Yanbian University,Yanji 133002,China)

机构地区：[1]延边大学医学院,吉林延吉133002 [2]山东医药大学烟台附属医院妇产科,山东烟台264000 [3]延边大学医学院预防医学教研室,吉林延吉133002

出　　处：《延边大学医学学报》2025年第2期72-78,共7页Journal of Medical Science Yanbian University

基　　金：吉林省卫生健康科技能力提升项目(编号:2021JC064)。

摘　　要：目的:通过Meta分析探索肿瘤细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)治疗卵巢癌的疗效与预后情况。方法:在The Cochrane Library、Web of Science、Pub Med、CBM、CNKI、VIP和万方数据库中,查找比较CRS联合HIPEC与单独CRS治疗卵巢癌的随机对照研究(RCT),对符合标准的文献进行审查、筛选、资料提取和质量评价,最后在Revman 5.3软件中对纳入文献进行Meta分析。结果:初次检索共获得620篇相关文献,最终纳入16个RCT,共计1366例患者。Meta分析结果表明:试验组临床有效率(OR=3.97;95%CI 2.85~5.54;P<0.001)、腹水控制率(OR=5.18;95%CI 2.84~9.44;P<0.001)、1年生存率(OR=1.99;95%CI 1.24~3.18;P=0.004)、CD4^(+)/CD8^(+)比值(MD=0.39;95%CI 0.36~0.42;P<0.001)均明显优于对照组,差异具有统计学意义;不良事件:胃肠道反应、骨髓抑制、肝功能不全方面,两组比较差异均无统计学意义。结论:CRS联合HIPEC治疗卵巢癌能够使患者在临床有效率、腹水控制率、生存率及免疫功能等方面获益,且不增加不良事件的发生率。Objective:To explore the efficacy and prognosis of cytoreductive surgery(CRS)combined with hyperthermic intraperitoneal chemotherapy(HIPEC)for ovarian cancer.Methods:Randomized controlled trials(RCT)comparing CRS combined with HIPEC and CRS alone for ovarian cancer were searched in The Cochrane Library,Web of Science,PubMed,CBM,CNKI,VIP and Wanfang databases.The literatures meeting the criteria were reviewed,screened,extracted and evaluated for quality,and finally meta-analysis was performed for the included literatures in Revman 5.3 software.Results:A total of 620 relevant literatures were obtained from the initial search,and 16 RCTs with a total of 1366 patients were finally included.The results of meta-analysis showed that the clinical effective rate(OR=3.97;95%CI 2.85~5.54;P<0.001),ascites control rate(OR=5.18;95%CI 2.84~9.44;P<0.001),1-year survival rate(OR=1.99;95%CI 1.24~3.18;P=0.004),and CD4^(+)/CD8^(+)ratio(MD=0.39;95%CI 0.36~0.42;P<0.001)of the experimental group were significantly better than those of the control group,with statistically significant differences.Adverse events:gastrointestinal reactions,myelosuppression and hepatic insufficiency were not statistically significant between the two groups.Conclusion:CRS combined with HIPEC for ovarian cancer can benefit patients in terms of efficiency,ascites control rate,survival rate and immune function,and does not increase the incidence of adverse events.

关 键 词：卵巢癌 肿瘤细胞减灭术 腹腔热灌注化疗 META分析 

分 类 号：R737.31[医药卫生—肿瘤]